These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28322894)

  • 1. Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics.
    de Zafra CLZ; Sasseville VG; Matsumoto S; Freichel C; Milton M; MacLachlan TK; Farman C; Raymond I; Gupta S; Newton R; Atzpodien EA; Thackaberry EA
    Regul Toxicol Pharmacol; 2017 Jun; 86():221-230. PubMed ID: 28322894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
    Ponce R; Abad L; Amaravadi L; Gelzleichter T; Gore E; Green J; Gupta S; Herzyk D; Hurst C; Ivens IA; Kawabata T; Maier C; Mounho B; Rup B; Shankar G; Smith H; Thomas P; Wierda D
    Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practice.
    Namdari R; Jones K; Chuang SS; Van Cruchten S; Dincer Z; Downes N; Mikkelsen LF; Harding J; Jäckel S; Jacobsen B; Kinyamu-Akunda J; Lortie A; Mhedhbi S; Mohr S; Schmitt MW; Prior H
    Regul Toxicol Pharmacol; 2021 Nov; 126():105029. PubMed ID: 34455009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Development of EBI-005: An IL-1 Receptor-1 Inhibitor for the Topical Ocular Treatment of Ocular Surface Inflammatory Diseases.
    Kovalchin J; King B; Masci A; Hopkins E; Fry J; Hou J; Li C; Tenneson K; Weber S; Wolfe G; Collins K; Furfine ES
    Eye Contact Lens; 2018 May; 44(3):170-181. PubMed ID: 28727604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New challenges and opportunities in nonclinical safety testing of biologics.
    Baumann A; Flagella K; Forster R; de Haan L; Kronenberg S; Locher M; Richter WF; Theil FP; Todd M
    Regul Toxicol Pharmacol; 2014 Jul; 69(2):226-33. PubMed ID: 24755365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abuse liability assessment for biologic drugs - All molecules are not created equal.
    de Zafra CLZ; Markgraf CG; Compton DR; Hudzik TJ
    Regul Toxicol Pharmacol; 2018 Feb; 92():165-172. PubMed ID: 29199066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring rabbit as a nonrodent species for general toxicology studies.
    Sokolowski K; Turner PV; Lewis E; Wange RL; Fortin MC
    Toxicol Sci; 2024 Apr; 199(1):29-39. PubMed ID: 38374304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retina expression and cross-species validation of gene silencing by PF-655, a small interfering RNA against RTP801 for the treatment of ocular disease.
    Lee DU; Huang W; Rittenhouse KD; Jessen B
    J Ocul Pharmacol Ther; 2012 Jun; 28(3):222-30. PubMed ID: 22304497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre- and Postnatal Development of the Eye: A Species Comparison.
    Van Cruchten S; Vrolyk V; Perron Lepage MF; Baudon M; Voute H; Schoofs S; Haruna J; Benoit-Biancamano MO; Ruot B; Allegaert K
    Birth Defects Res; 2017 Nov; 109(19):1540-1567. PubMed ID: 28941218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum to "Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics" [Regul. Toxicol. Pharmacol. (2017) 221-230].
    de Zafra CLZ; Sasseville VG; Matsumoto S; Freichel C; Milton M; MacLachlan TK; Farman C; Raymond I; Gupta S; Newton R; Atzpodien EA; Thackaberry EA
    Regul Toxicol Pharmacol; 2017 Aug; 88():364. PubMed ID: 28431771
    [No Abstract]   [Full Text] [Related]  

  • 11. Nonclinical development of biopharmaceuticals.
    Baumann A
    Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety, efficacy and regulatory triangle in drug development: Impact for animal models and the use of animals.
    van Meer PJ; Graham ML; Schuurman HJ
    Eur J Pharmacol; 2015 Jul; 759():3-13. PubMed ID: 25818943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The application of ICH S6 to the preclinical safety evaluation of plasma derivative therapeutic products.
    Lewis RM; Cavagnaro J
    Biologicals; 2010 Jul; 38(4):494-500. PubMed ID: 20359910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The SPOTS System: An Ocular Scoring System Optimized for Use in Modern Preclinical Drug Development and Toxicology.
    Eaton JS; Miller PE; Bentley E; Thomasy SM; Murphy CJ
    J Ocul Pharmacol Ther; 2017 Dec; 33(10):718-734. PubMed ID: 29239680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonclinical Development of Biologics: Integrating Safety, Pharmacokinetics, and Pharmacodynamics to Create Smarter and More Flexible Nonclinical Safety Programs Optimizing Animal Use.
    Hey A; Baumann A; Kronenberg S; Blaich G; Mohl S; Fagg R; Ulrich P; Rattel B; Richter WF; Kiessling A; Weir L
    Int J Toxicol; 2021; 40(3):270-284. PubMed ID: 33631988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational Safety Genetics.
    Bhoumik P; Del Rio-Espinola A; Hahne F; Moggs J; Grenet O
    Toxicol Pathol; 2017 Jan; 45(1):119-126. PubMed ID: 27932582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.
    Brennan FR; Andrews L; Arulanandam AR; Blumel J; Fikes J; Grimaldi C; Lansita J; Loberg LI; MacLachlan T; Milton M; Parker S; Tibbitts J; Wolf J; Allamneni KP
    Regul Toxicol Pharmacol; 2018 Oct; 98():98-107. PubMed ID: 30026135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory Forum Opinion Piece
    Morgan SJ; Couch J; Guzzie-Peck P; Keller DA; Kemper R; Otieno MA; Schulingkamp RJ; Jones TW
    Toxicol Pathol; 2017 Apr; 45(3):372-380. PubMed ID: 28351296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. General considerations in ocular toxicity risk assessment from the toxicologists' viewpoints.
    Onodera H; Sasaki S; Otake S; Tomohiro M; Shibuya K; Nomura M
    J Toxicol Sci; 2015 Jun; 40(3):295-307. PubMed ID: 25972191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.